Expert Interviews
Giorgio Trinchieri, MD, on Fecal Microbiota Transplant to Promote Immunotherapy Response
February 26th 2021Giorgio Trinchieri, MD, of the National Cancer Institute’s Center for Cancer Research joined CancerNetwork® to discuss enhancing the gut microbiome by way of fecal transplant for better immunotherapy responses.
Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER
February 25th 2021In the phase 3 CheckMate 9ER trial, investigators found that nivolumab plus cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously untreated advanced renal cell carcinoma.
Former CMO and Execute VP of ASCO on Molecular Profiling in GI Cancer and Health Inequity
February 23rd 2021Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the organization’s top priorities are in the near future.
Timothy A. Yap, MBBS, PhD, FRCP, on COVID-19 Vaccination for Patients in Phase 1 Cancer Trials
February 19th 2021The medical oncologist and physician scientist based at the University of Texas MD Anderson Cancer Center explained recommendations for SARS-CoV-2 vaccination in patients participating in phase 1 oncology clinical trials.
Salma Jabbour, MD, on the Results of the Ongoing KEYNOTE-799 Study
February 17th 2021The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed updated results from the study of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
Jonathan Thompson, MD, MS, on AEs and Limitations Reported in the Phase 2 BGBC008 Study
February 15th 2021The trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.
Relapsed/Refractory HER2+ Metastatic Breast Cancer
February 15th 2021Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.
